Uncovering a neurological protein signature for severe COVID-19

[1]  S. Rizzo,et al.  Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei , 2023, npj Parkinson's Disease.

[2]  B. Mollenhauer,et al.  Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease , 2022, Movement disorders : official journal of the Movement Disorder Society.

[3]  G. Nordvall,et al.  Neurotrophin-targeted therapeutics: a gateway to cognition and more? , 2022, Drug discovery today.

[4]  I. Koralnik,et al.  Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection , 2022, Neurology: Neuroimmunology & Neuroinflammation.

[5]  F. Al-Ejeh,et al.  Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications , 2022, Nature communications.

[6]  J. Kuhle,et al.  Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response , 2022, Therapeutic advances in neurological disorders.

[7]  Daniel M. Lidar,et al.  Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort , 2021, Science Translational Medicine.

[8]  Arvid Edén,et al.  Author Response: CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series , 2021, Neurology.

[9]  H. Shah,et al.  Molecular Profiling of Coronavirus Disease 2019 (COVID-19) Autopsies Uncovers Novel Disease Mechanisms , 2021, The American Journal of Pathology.

[10]  J. Geddes,et al.  Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 , 2021, PLoS medicine.

[11]  K. Blennow,et al.  Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up , 2021, EBioMedicine.

[12]  M. Fowkes,et al.  Single-nucleus transcriptome analysis of human brain immune response in patients with severe COVID-19 , 2021, Genome medicine.

[13]  H. Zetterberg,et al.  Neurochemical biomarkers to study CNS effects of COVID‐19: A narrative review and synthesis , 2021, Journal of neurochemistry.

[14]  I. Cobos,et al.  Dysregulation of brain and choroid plexus cell types in severe COVID-19 , 2021, Nature.

[15]  J. Saez-Rodriguez,et al.  Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions , 2021, Immunity.

[16]  S. Coldewey,et al.  Neurofilament Light Chain in Patients with COVID‐19 and Bacterial Pneumonia , 2021, Annals of neurology.

[17]  M. Filippi,et al.  Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients , 2021, Journal of Neurology.

[18]  Paul J. Hoover,et al.  Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions , 2021, Cell Reports Medicine.

[19]  J. Kuhle,et al.  Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19 , 2021, Journal of Neurology.

[20]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[21]  M. Peluso,et al.  Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations , 2021, Cells.

[22]  Greta Limoni,et al.  Semaphorins and Plexins in central nervous system patterning: the key to it all? , 2021, Current Opinion in Neurobiology.

[23]  Kevin K. W. Wang,et al.  Thorough overview of ubiquitin C‐terminal hydrolase‐L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury , 2021, Acute medicine & surgery.

[24]  L. Kappos,et al.  Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019 , 2020, Annals of neurology.

[25]  K. Blennow,et al.  Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity , 2020, European journal of neurology.

[26]  Wenzhe Ho,et al.  Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID‐19 , 2020, Journal of medical virology.

[27]  A. Baig.  Chronic COVID syndrome: Need for an appropriate medical terminology for long‐COVID and COVID long‐haulers , 2020, Journal of medical virology.

[28]  J. Gostner,et al.  CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms , 2020, Neurology.

[29]  Renato Oliveira,et al.  NeuroCOVID: critical review of neuropsychiatric manifestations of SARS-CoV-2 infection , 2020, Irish Journal of Medical Science (1971 -).

[30]  O. Sinanović,et al.  COVID-19 Pandemia: Neuropsychiatric Comorbidity and Consequences. , 2020, Psychiatria Danubina.

[31]  Madeleine K. D. Scott,et al.  Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.

[32]  R. Bertollini,et al.  The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study , 2020, BMC Infectious Diseases.

[33]  Maria Thom,et al.  The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings , 2020, Brain : a journal of neurology.

[34]  D. Strambo,et al.  Transverse myelitis related to COVID-19 infection , 2020, Journal of Neurology.

[35]  P. Matthews,et al.  Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study , 2020, The Lancet Psychiatry.

[36]  J. Bergquist,et al.  Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid , 2020, Neurology.

[37]  M. Versino,et al.  Reversible Encephalopathy Syndrome (PRES) in a COVID-19 patient , 2020, Journal of Neurology.

[38]  K. Blennow,et al.  Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 , 2020, Neurology.

[39]  E. Roze,et al.  Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection , 2020, Journal of Neurology.

[40]  J. Kuhle,et al.  Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19 , 2020, Journal of Neurology.

[41]  A. Alexandrov,et al.  Neurological manifestations and implications of COVID-19 pandemic , 2020, Therapeutic advances in neurological disorders.

[42]  L. Wojtecki,et al.  Non-epileptic seizures in autonomic dysfunction as the initial symptom of COVID-19 , 2020, Journal of Neurology.

[43]  Paolo Fusar-Poli,et al.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[44]  J. McArthur,et al.  Neurological manifestations associated with COVID-19: a review and a call for action , 2020, Journal of Neurology.

[45]  S. Kremer,et al.  Neurologic Features in Severe SARS-CoV-2 Infection , 2020, The New England journal of medicine.

[46]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[47]  David A. Lewis,et al.  Postmortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder , 2019, Translational Psychiatry.

[48]  Eun Woo Son,et al.  iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data , 2018, BMC Bioinformatics.

[49]  E. Stopa,et al.  Choroid plexus genes for CSF production and brain homeostasis are altered in Alzheimer’s disease , 2018, Fluids and Barriers of the CNS.

[50]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[51]  S. Funikov,et al.  FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy , 2018, neurogenetics.

[52]  Miles C. Miller,et al.  Comparative transcriptomics of choroid plexus in Alzheimer’s disease, frontotemporal dementia and Huntington’s disease: implications for CSF homeostasis , 2018, Fluids and Barriers of the CNS.

[53]  C. Faivre-Sarrailh,et al.  ADAM22 and ADAM23 modulate the targeting of the Kv1 channel-associated protein LGI1 to the axon initial segment , 2018, Journal of Cell Science.

[54]  J. Trojanowski,et al.  Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s disease , 2018, Nature Neuroscience.

[55]  G. Fuellen,et al.  ADAM23 promotes neuronal differentiation of human neural progenitor cells , 2017, Cellular & Molecular Biology Letters.

[56]  K. Brennand,et al.  Common developmental genome deprogramming in schizophrenia — Role of Integrative Nuclear FGFR1 Signaling (INFS) , 2017, Schizophrenia Research.

[57]  J. Buxbaum,et al.  Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer’s disease , 2016, Genome Medicine.

[58]  Silvio C. E. Tosatto,et al.  Secretion-Positive LGI1 Mutations Linked to Lateral Temporal Epilepsy Impair Binding to ADAM22 and ADAM23 Receptors , 2016, PLoS genetics.

[59]  M. Staufenbiel,et al.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.

[60]  J. Rapoport,et al.  Dysregulation of miRNA-9 in a Subset of Schizophrenia Patient-Derived Neural Progenitor Cells. , 2016, Cell reports.

[61]  K. Brennand,et al.  Altered WNT Signaling in Human Induced Pluripotent Stem Cell Neural Progenitor Cells Derived from Four Schizophrenia Patients , 2015, Biological Psychiatry.

[62]  H. Freeze,et al.  Neurological aspects of human glycosylation disorders. , 2015, Annual review of neuroscience.

[63]  Samira N. Kashefi,et al.  Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study , 2015, Journal of Neural Transmission.

[64]  Kenneth S. Kosik,et al.  Robust Axonal Regeneration Occurs in the Injured CAST/Ei Mouse CNS , 2015, Neuron.

[65]  A. Micera,et al.  Nerve Growth Factor: A Focus on Neuroscience and Therapy , 2015, Current neuropharmacology.

[66]  Hester F. Lingsma,et al.  Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. , 2015, Journal of neurotrauma.

[67]  Eric E Schadt,et al.  iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. , 2014, Cell reports.

[68]  J Gautrais,et al.  Beyond boundaries—Eph:ephrin signaling in neurogenesis , 2014, Cell adhesion & migration.

[69]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[70]  Jia Qian Wu,et al.  RNA-Seq Characterization of Spinal Cord Injury Transcriptome in Acute/Subacute Phases: A Resource for Understanding the Pathology at the Systems Level , 2013, PloS one.

[71]  A. Faden,et al.  TrkB.T1 Contributes to Neuropathic Pain after Spinal Cord Injury through Regulation of Cell Cycle Pathways , 2013, The Journal of Neuroscience.

[72]  Carl W. Cotman,et al.  Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease , 2013, Neurobiology of Aging.

[73]  M. Bernardo,et al.  Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies , 2013, European Neuropsychopharmacology.

[74]  Shiying Li,et al.  Differential Gene Expression Profiling and Biological Process Analysis in Proximal Nerve Segments after Sciatic Nerve Transection , 2013, PloS one.

[75]  Samira N. Kashefi,et al.  Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study , 2012, Acta Neuropathologica.

[76]  B. Su,et al.  [Association of the schizophrenia susceptible gene DKK4 with brain volume in Chinese populations]. , 2011, Dong wu xue yan jiu = Zoological research.

[77]  Nicholas Eriksson,et al.  Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease , 2011, PLoS genetics.

[78]  M. Ronaghi,et al.  Ontology-Based Meta-Analysis of Global Collections of High-Throughput Public Data , 2010, PloS one.

[79]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[80]  Pall I. Olason,et al.  Common variants conferring risk of schizophrenia , 2009, Nature.

[81]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[82]  J. Lieberman,et al.  Genomewide association for schizophrenia in the CATIE study: results of stage 1 , 2008, Molecular Psychiatry.

[83]  A. Yaron,et al.  Navigating their way to the clinic: Emerging roles for axon guidance molecules in neurological disorders and injury , 2007, Developmental neurobiology.

[84]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[85]  S. Guthrie.  Neurotrophic factors: are they axon guidance molecules? , 2007, Advances in experimental medicine and biology.